Building matrices ( to answer my PICO question) Assignment

Building matrices ( to answer my PICO question) - Assignment Example It would have been externally valid if it had selected a sample that would represent a larger population. However, it might be still useful as a primary source. The study yielded reliable and valid results, but it would have been improved by ensuring that a study group instead of the caregivers controlled the medications. Additionally, most caregivers are family members who have les education on the actual purpose of drug administration. Adler, G., Mueller, B., & Articus, K. (2014). The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimers disease under daily practice conditions. Int J Clin Pract, 68(4), 465-470. doi:10.1111/ijcp.12374 Arranz, F., & LÃÆ' ³pez-Pousa, S. (2013). Characteristics of patients with Alzheimer’s disease who switch to rivastigmine transdermal patches in routine clinical practice. PPA, 47. doi:10.2147/ppa.s38719 Andrade-dos-Santos, G., Canineu, P., Pardi, P., & GonÃÆ' §alves, I. (2011). Influence of Rivastigmine transdermal on butyrylcholinesterase levels in patients with Alzheimerà ¢Ã¢â€š ¬Ã¢â€ž ¢s disease. Alzheimers & Dementia, 5(4), 332-336. Gauthier, S., Robillard, A., Cohen, S., Black, S., Sampalis, J., & Colizza, D. et al. (2013). Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimerà ¢Ã¢â€š ¬Ã¢â€ž ¢s disease: the EMBRACE study. Curr Med Res Opin, 29(8), 989-1000. doi:10.1185/03007995.2013.802230 Moretti, D., Frisoni, G., Binetti, G., & Zanetti, O. (2014). Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with AlzheimerÃÆ' ¢Ãƒ ¢Ã¢â‚¬Å¡Ã‚ ¬Ãƒ ¢Ã¢â‚¬Å¾Ã‚ ¢s disease. Frontiers In Aging Neuroscience, 6.